GlassScriptPhysician profile
Loan Thuy Retchless
NPI 1295784262
$21,470.43
in general payments reported to CMS, 2019-2025
73 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,338 · 2022: $5,212 · 2023: $5,732 · 2024: $4,015 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,670 · Education: $917 · Long Term Medical Supply Or Device Loan: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,669.51 |
| Education | $917.48 |
| Long Term Medical Supply Or Device Loan | $333.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,566.36 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,682.74 | 2021-2024 | Enhertu, Calquence, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $1,594.45 | 2021-2025 | Opdivo, Opdualag, Augtyro |
| Astellas Pharma US INC | $1,551.71 | 2021-2025 | Xospata, Vyloy, Xtandi |
| Seagen INC. | $940.74 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Pfizer INC. | $782.59 | 2021-2024 | |
| Lilly USA, LLC | $760.03 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $683.52 | 2021-2024 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $677.88 | 2021-2024 | Reblozyl, Pomalyst |
| Amgen INC. | $675.22 | 2021-2023 | Lumakras |
| Pharmacyclics LLC, An Abbvie Company | $644.02 | 2021-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $615.98 | 2021-2025 | Monjuvi, Monjuvi, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $602.25 | 2021-2024 | |
| Janssen Biotech, INC. | $504.60 | 2021-2024 | Darzalex, Tecvayli, Imbruvica |
| Boehringer Ingelheim Pharmaceuticals, INC. | $429.04 | 2021-2024 | Gilotrif |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $412.98 | 2022-2025 | Orserdu, Elzonris |
| Daiichi Sankyo INC. | $381.26 | 2021-2024 | Enhertu |
| Taiho Oncology, INC. | $373.94 | 2021-2025 | |
| Adc Therapeutics America, INC. | $365.40 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $311.64 | 2021-2024 | Libtayo |
| Glaxosmithkline, LLC. | $301.54 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Beigene USA, INC. | $301.20 | 2021-2024 | Brukinsa |
| Sobi, INC | $299.98 | 2022-2024 | |
| Tersera Therapeutics LLC | $296.67 | 2021-2024 | Zoladex, Quzyttir |
| Abbvie INC. | $294.99 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $286.71 | 2021-2024 | Alunbrig, Iclusig |
| Beone Medicines USA, INC. | $285.03 | 2025 | Tevimbra, Brukinsa |
| Kite Pharma, INC. | $191.14 | 2021-2023 | Yescarta |
| Genmab U.S., INC. | $123.81 | 2023-2024 | Epkinly |
| Adma Biomanufacturing LLC | $122.49 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $107.47 | 2021-2024 | Tavalisse, Rezlidhia |
| Array Biopharma INC | $106.29 | 2021-2024 | Lorbrena, Braftovi, Xalkori |
| Exelixis INC. | $104.68 | 2023-2024 | Cabometyx |
| Apellis Pharmaceuticals, INC. | $101.65 | 2023-2024 | Empaveli |
| Emd Serono, INC. | $101.45 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $91.29 | 2021-2024 | Onivyde, Tazverik |
| Acrotech Biopharma INC. | $87.18 | 2023-2024 | Beleodaq |
| Eisai INC. | $87.08 | 2021-2024 | |
| Myriad Genetic Laboratories, INC. | $82.57 | 2021-2022 | |
| Morphosys, US INC. | $82.14 | 2021 | |
| Myovant Sciences INC. | $81.32 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $77.99 | 2022 | |
| Blueprint Medicines Corporation | $77.27 | 2021-2022 | |
| Genzyme Corporation | $76.19 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $75.58 | 2022-2024 | Monoferric |
| G1 Therapeutics, INC. | $68.94 | 2022 | |
| Aveo Pharmaceuticals, INC. | $68.47 | 2022-2024 | Fotivda |
| Gilead Sciences, INC. | $65.26 | 2021-2024 | |
| Tg Therapeutics, INC. | $65.08 | 2022 | |
| Genentech USA, INC. | $64.88 | 2021-2023 | Polivy, Lunsumio, Phesgo |
| Heron Therapeutics, INC. | $62.67 | 2021-2022 | |
| Acceleron Pharma, INC. | $58.96 | 2021 | |
| Epizyme, INC. | $50.55 | 2021 | |
| Tempus Ai, INC | $49.98 | 2024 | |
| Coherus Oncology, INC. | $45.87 | 2021-2023 | |
| Puma Biotechnology, INC. | $45.83 | 2021-2023 | |
| Ge Healthcare | $44.50 | 2022 | |
| Deciphera Pharmaceuticals INC. | $40.12 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $38.82 | 2021 | |
| Mirati Therapeutics, INC. | $36.45 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $30.60 | 2022 | |
| Springworks Therapeutics, INC. | $29.76 | 2024 | Ogsiveo |
| Cti Biopharma Corp. | $27.58 | 2022 | |
| Organon LLC | $24.65 | 2024 | |
| Accord Healthcare, INC. | $21.64 | 2024 | |
| Dova Pharmaceuticals | $21.56 | 2021 | |
| Pharmaessentia USA Corporation | $19.54 | 2023 | Besremi |
| Tactile Systems Technology INC | $18.28 | 2021 | |
| Octapharma USA, INC. | $17.19 | 2024 | Octagam Immune Globulin (Human) |
| Novocure INC. | $15.66 | 2025 | Optune Lua (Novottf-200t) |
| Sun Pharmaceutical Industries INC. | $13.93 | 2022 | |
| Servier Pharmaceuticals LLC | $13.66 | 2022 | |
| Janssen Pharmaceuticals, INC | $9.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loan Retchless listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.